MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: Results from 484 patients of multicenter trial NHL-BFM 95

Annals of Hematology

Volumn 85, Issue 5, 2006, Pages 291-300

  Seidemann, Kathrin ^a   Book, Marion ^a   Zimmermann, Martin ^a   Meyer, Ulrike ^b   Welte, Karl ^a   Stanulla, Martin ^a   Reiter, Alfred ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

BFM; MTHFR; NHL; Pediatric; Polymorphism; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; FOLINIC ACID; LACTATE DEHYDROGENASE; METHOTREXATE;

ALLELE; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG FEVER; DRUG MEGADOSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER TOXICITY; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; T CELL LYMPHOMA;

ADOLESCENT; AGE FACTORS; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HOMOZYGOTE; HUMANS; LYMPHOMA, LYMPHOBLASTIC; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 33646677710     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0072-2     Document Type: Article

References (48)

1. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T (2005) Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 15:2482-2487
2. Bennett JM, Catorsky D, Daniel MT et al (1976) Proposal for the classification of the acute leukemias. French-American-British (FAB) Cooperative Groups. Br J Heamatol 33:451-458
3. Botto LD, Yang Q (2000) 5,10-methylentetrahydrofolate reductase gene variations and congenital anomalies: A HuGE review. Am J Epidemiol 151:862-877
4. Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L, Leone G, Sica S (2002) Preponderance of methylenetetrahydrofolate reductase C677 homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13:1915-1918
5. Chiusolo P, Reddiconto G, Cimino G, Sica S, Fiorini A, Farina G, Vitale A, Sorà F, Laurenti L, Bartolozzi F, Fazi P, Mandelli F, Leone G (2004) Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica 89:139-144
6. Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187-220
7. Evans WE (2002) Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics 12:181-182
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Metthews RG, Boers GHJ, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: A common mutation in methyleneterahydrofolate reductase. Nature Genet 10:111-114
9. Frosst P, Zhang Z-X, Pai A, Rozen R (1996) The methylenetetrahydrofolate reductase (MTHFR) gene maps to distal mouse chromosome 4. Mamm Genome 7:864-869
10. Gemmati D, Ongaro A, Scapoli GL, Della Porta M, Reverberi R, Caruso A, Pasello M, Pellati A, De Mattei M (2004) Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 13:787-794
11. Goyette P, Rozen R (2000) The thermolabile variant 677C-T can further reduce activity when expressed in CIS with severe mutations for human methylenetetrahydrofolate reductase. Hum Mutat 16:132-138
12. Greenwood M (1926) A report on the natural duration of cancer. In: Reports on public health and medical subjects. Ministry of Health, Her Majesty's Statistical Office, London, pp 1-26
13. Harris NL (1997) Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group). Annals Oncol 8:11-16
14. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9
15. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
16. Kishi K, Griener J, Cheng C, Das S, DCook E, Pei D, Hudson M, Rubnitz J, Sandlund JT, Pui C-H, Relling MV (2003) Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21:3084-3091
17. Koch MC, Stegmann K, Ziegler A, Schroter B, Ermert A (1998) Evaluation of thr MTHFR C677T allele and the MTHFR gene in a German spina bifida population. Eur J Pediatr 157:487-492
18. Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, ThéoRêt Y, Moghrabi A, Sinnett D (2004) Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103:252-257
19. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics 4:66-72
20. Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M, Primeau M, Bournissen FG, Moghrabi A (2005) Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 6:293-302
21. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170
22. Martinelli M, Scapoli L, Pezzetti F, Carinci F, Stabellini G, Bisceglia L, Gombos F, Tognon M (2001) C677T variant form at the MTHFR gene and CL/ P: A risk factor for mothers? Am J Hum Genet 98:357-360
23. Matsuo K, Suzuki R, Hamajima M, Ogura M, Kagami Y, Taji H, Kondoh E, Maeda S, Asakura S, Kaba S, Nakamura S, Seto M, Morishima Y, Tajima K (2001) Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant disease. Blood 97:3205-3209
24. Mogk RL, Rothenmund H, Evans JA, Carson N, Dawson AJ (2000) The frequency of the C677T substitution in the methylenetetrahydrofolate reductase gene in Manitoba. Clin Genet 58:406-408
25. Mornet E, Muller F, Lanvoise-Furet A, Delezoide A-L, Col J-Y, Soimon-Bouy B, Serre J-L (1997) Screening the C677T mutation on the methylenetetrahydrofolate reductase gene in French patients with neural tube defects. Hum Genet 100:512-514
26. Ogino S, Wilson RB (2003) Genotype and haplotype distributions of MTHFR 677 C>T and 1298 A>C single nucleotide polymorphisms: A meta-analysis. J Hum Genet 48:1-7
27. Ortega M, Gomez-de-Segura IA, Vazquez I, Lopez JM, de Guevara CL, De-Miguel E (2001) Effects of growth hormone plus a hyperproteic diet on methotrexate-induced injury in rat intestines. Acta Oncol 40:615-621
28. Papapetrou C, Lynch SA, Burn J, Edwards YH (1996) Methylenetetrahydrofolate reductase and neural tube defects. Lancet 348:58-58
29. Patte C, Leverger G, Rubie H, Bertrand Y, Coze C, Méchinaud F, Lutz P, Michon J, Baruchel A, Courbon B (1993) High cure rate in B-cell (Burkitt's) leukemia in the LMB 89 protocol of the SFOP (French Pediatric Oncology Society) (abstract). Proc ASCO 12:317
30. Reinhardt D, Sigusch HH, Vogt SF, Farker K, Muller S, Hoffmann G (1998) Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest 28:20-23
31. Reiter A, Schrappe M, Parwaresch R, Henze G, Müller-Weihrich S, Sauter S, Sykora K-W, Ludwig W-D, Gadner H, Riehm H (1995) Non-Hodgkin's lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol 13:359-372
32. Reiter A, Schrappe M, Ludwig W-D, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H (1999) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report. Blood 95:416-421
33. Reiter A, Schrappe M, Tiemann M, Ludwig W-D, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Plüss H-J, Zintl F, Henze G, Riehm H (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 94:3294-3306
34. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka Schaub G, Dörffel W, Zimmermann M, Mann G, Gadner H, Riehm H, Reiter A (2001) Short-pulse B-non-Hodgkin lymphoma type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97:3699-3706
35. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G (1999) Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 96:12810-12815
36. Skibola CF, Forrest MS, Coppedé F, Agana L, Hubbard A, Smith MT, Bracci PM, Holly EA (2004) Polymorphisms and haplotypes in folate metabolizing genes and risk of non-Hodgkin lymphoma. Blood 104:2155-2162
37. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T (1997) Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 34:525-526
38. Stansfeld AG, Diebold J, Kapanci Y, Noel H, Rilke F, Kelenyi G, Sundstrom C, Lennert J, van Unnik JA, Mioduszewska O (1988) Updated Kiel classification for lymphomas. Lancet 1:292-293
39. Stevenson M, Schwartz CE, Du Y-Z, Adams MJ (1997) Differences in methylenetetrahydrofolate reductase genotype frequencies between whites and blacks. Am J Hum Genet 60:229-230
40. Toffoli G, Veronesi A, Boiocchi M, Crivellari D (2000) MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluouracil (CMF). Ann Oncol 11:373-374
41. Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A (2003) Methylenetetrahydrofolate reductase genotype in diffuse large cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers 18:218-221
42. Ulrich CM, Storb R, Schubert MM, Potter JD (2001) MTHFR polymorphism, DNA repair capacity, and methotrexate toxicity. Blood 98:2283-2283
43. Ulrich CM, Robien K, Sparks R (2002) Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 3:299-313
44. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated both with the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analysis. Pharmacogenetics 12:183-190
45. van der Put NM, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKA, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070-1071
46. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, de Boo TM, van der Putte LB (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525-2530
47. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF (2001) Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk factor of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 98:4004-4009
48. Wössmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Jürgens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescence with B-cell neoplasms: A report of the BFM Study Group NHL-BFM 95. Blood 105:948-958